Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma

被引：0
|
作者：
Kotasek, Dusan
Nagrial, Adnan
Lumba, Sumit
Tebbutt, Niall C.
George, Thomas J.
Smith, Sheri Lynn
Gagnon, Suzanne
Cullen, Michael T.
Walker, Michael J.
机构：
[1] Univ Adelaide, Adelaide, SA, Australia
[2] Blacktown Hosp, Canc & Haematol Ctr, Blacktown, NSW, Australia
[3] John Flynn Private Hosp, Canc & Haematol Ctr, Tugun, Qld, Australia
[4] Heidelberg Repatriat Hosp, AfA A A, Olivia Newton John Canc & Wellness Ctr, Heidelberg, Vic, Australia
[5] Univ Florida, Hlth Canc Ctr, Gainesville, FL USA
[6] Courante Oncol, Excelsior, MN USA
[7] Sun BioPharma Inc, Jamestown, RI USA
[8] Sun BioPharma Inc, Waconia, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
710
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Efficacy of SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, as a first-line treatment for patients with metastatic pancreatic ductal adenocarcinoma
    Singhal, Nimit
    Sigal, Darren
    Tebbutt, Niall C.
    Hezel, Aram F.
    Nagrial, Adnan
    Lumba, Sumit
    George, Thomas J.
    Smith, Sheri Lynn
    Gagnon, Suzanne
    Cullen, Michael T.
    Walker, Michael
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [2] SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.
    Singhal, Nimit
    Sigal, Darren
    Tebbutt, Niall C.
    Hezel, Aram F.
    Nagrial, Adnan
    Lumba, Sumit
    George, Thomas J.
    Smith, Sheri Lynn
    Gagnon, Suzanne
    Walker, Michael
    Cullen, Michael T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [3] Efficacy of SBP-101 With or Without Gemcitabine and/or Nab-paclitaxel in a Murine Xenograft Model of Human Pancreatic Ductal Adenocarcinoma
    Shah, A.
    Gagnon, S.
    de Marval, P. Milani
    Kiorpes, A.
    Cullen, M.
    [J]. PANCREAS, 2015, 44 (08) : 1413 - 1414
  • [4] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Pat Gulhati
    Laura Prakash
    Matthew H. G. Katz
    Xuemei Wang
    Milind Javle
    Rachna Shroff
    David Fogelman
    Jeffrey E. Lee
    Ching-Wei D. Tzeng
    Jeffrey H. Lee
    Brian Weston
    Eric Tamm
    Priya Bhosale
    Eugene J. Koay
    Anirban Maitra
    Huamin Wang
    Robert A. Wolff
    Gauri R. Varadhachary
    [J]. Annals of Surgical Oncology, 2019, 26 : 619 - 627
  • [5] First-Line Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
    Gulhati, Pat
    Prakash, Laura
    Katz, Matthew H. G.
    Wang, Xuemei
    Javle, Milind
    Shroff, Rachna
    Fogelman, David
    Lee, Jeffrey E.
    Tzeng, Ching-Wei D.
    Lee, Jeffrey H.
    Weston, Brian
    Tamm, Eric
    Bhosale, Priya
    Koay, Eugene J.
    Maitra, Anirban
    Wang, Huamin
    Wolff, Robert A.
    Varadhachary, Gauri R.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (02) : 619 - 627
  • [6] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    P. G. Corrie
    W. Qian
    B. Basu
    J. W. Valle
    S. Falk
    C. lwuji
    H. Wasan
    D. Palmer
    M. Scott-Brown
    J. Wadsley
    S. Arif
    J. Bridgewater
    D. Propper
    R. Gillmore
    A. Gopinathan
    R. Skells
    P. Bundi
    R. Brais
    K. Dalchau
    L. Bax
    A. Chhabra
    A. Machin
    A. Dayim
    K. McAdam
    S. Cummins
    L. Wall
    R. Ellis
    A. Anthoney
    J. Evans
    Y. T. Ma
    C. Isherwood
    A. Neesse
    D. Tuveson
    D. I. Jodrell
    [J]. British Journal of Cancer, 2020, 122 : 1760 - 1768
  • [7] Scheduling nab-paclitaxel combined with gemcitabine as first-line treatment for metastatic pancreatic adenocarcinoma
    Corrie, P. G.
    Qian, W.
    Basu, B.
    Valle, J. W.
    Falk, S.
    Iwuji, C.
    Wasan, H.
    Palmer, D.
    Scott-Brown, M.
    Wadsley, J.
    Arif, S.
    Bridgewater, J.
    Propper, D.
    Gillmore, R.
    Gopinathan, A.
    Skells, R.
    Bundi, P.
    Brais, R.
    Dalchau, K.
    Bax, L.
    Chhabra, A.
    Machin, A.
    Dayim, A.
    McAdam, K.
    Cummins, S.
    Wall, L.
    Ellis, R.
    Anthoney, A.
    Evans, J.
    Ma, Y. T.
    Isherwood, C.
    Neesse, A.
    Tuveson, D.
    Jodrell, D., I
    [J]. BRITISH JOURNAL OF CANCER, 2020, 122 (12) : 1760 - 1768
  • [8] Efficacy and safety of sintilimab combined nab-paclitaxel and gemcitabine as first-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC): A retrospective analysis
    Wang, J.
    He, Y.
    Lv, H.
    Chen, B.
    Nie, C.
    Xu, W.
    Zhao, J.
    Zhang, B.
    Cheng, X.
    Li, Q.
    Tu, S.
    Chen, X.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 : S247 - S247
  • [9] Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric A.
    Aran, Dvir
    [J]. JAMA NETWORK OPEN, 2022, 5 (06) : E2216199
  • [10] Ibrutinib in combination with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma: phase III RESOLVE study
    Tempero, M.
    Oh, D-Y
    Tabernero, J.
    Reni, M.
    Van Cutsem, E.
    Hendifar, A.
    Waldschmidt, D-T
    Starling, N.
    Bachet, J-B
    Chang, H-M
    Maurel, J.
    Garcia-Carbonero, R.
    Lonardi, S.
    Coussens, L. M.
    Fong, L.
    Tsao, L. C.
    Cole, G., Jr.
    James, D.
    Macarulla, T.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 (05) : 600 - 608
12345